# A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

> **NCT05559125** · PHASE1 · TERMINATED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 50 (actual)

## Conditions studied

- Healthy Subject

## Interventions

- **DRUG:** STSA-1002 Injection
- **DRUG:** STSA-1005 Injection

## Key facts

- **NCT ID:** NCT05559125
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-08
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-03-26
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559125, "A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05559125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*